AU2018331371C1 - A novel small molecule compound - Google Patents

A novel small molecule compound Download PDF

Info

Publication number
AU2018331371C1
AU2018331371C1 AU2018331371A AU2018331371A AU2018331371C1 AU 2018331371 C1 AU2018331371 C1 AU 2018331371C1 AU 2018331371 A AU2018331371 A AU 2018331371A AU 2018331371 A AU2018331371 A AU 2018331371A AU 2018331371 C1 AU2018331371 C1 AU 2018331371C1
Authority
AU
Australia
Prior art keywords
disease
cancer
cpt
mitochondrial
condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018331371A
Other languages
English (en)
Other versions
AU2018331371A1 (en
AU2018331371B2 (en
Inventor
Bingwei Lu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cerepeut LLC
Original Assignee
Cerepeut LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerepeut LLC filed Critical Cerepeut LLC
Publication of AU2018331371A1 publication Critical patent/AU2018331371A1/en
Publication of AU2018331371B2 publication Critical patent/AU2018331371B2/en
Application granted granted Critical
Publication of AU2018331371C1 publication Critical patent/AU2018331371C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AU2018331371A 2017-09-13 2018-09-12 A novel small molecule compound Active AU2018331371C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762558323P 2017-09-13 2017-09-13
US62/558,323 2017-09-13
PCT/US2018/050689 WO2019055528A1 (en) 2017-09-13 2018-09-12 NEW COMPOUND WITH SMALL MOLECULES

Publications (3)

Publication Number Publication Date
AU2018331371A1 AU2018331371A1 (en) 2020-04-02
AU2018331371B2 AU2018331371B2 (en) 2024-02-15
AU2018331371C1 true AU2018331371C1 (en) 2024-05-09

Family

ID=65723058

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018331371A Active AU2018331371C1 (en) 2017-09-13 2018-09-12 A novel small molecule compound

Country Status (9)

Country Link
US (3) US11186550B2 (enExample)
EP (1) EP3681874B1 (enExample)
JP (1) JP7170341B2 (enExample)
KR (1) KR102644045B1 (enExample)
CN (1) CN111372921B (enExample)
AU (1) AU2018331371C1 (enExample)
CA (1) CA3075649A1 (enExample)
IL (1) IL273242B2 (enExample)
WO (1) WO2019055528A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11186550B2 (en) 2017-09-13 2021-11-30 Cerepeut, Inc. Small molecule compound
KR20210139279A (ko) * 2019-02-27 2021-11-22 셀리퓨트, 인코포레이티드 퀴나졸리논 화합물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051974A2 (en) * 2003-06-09 2005-06-09 The Regents Of The University Of California Novel molecules for regulating cell death
US8759097B2 (en) * 2011-04-19 2014-06-24 University of Pittsburgh—of the Commonwealth System of Higher Eduction Inhibition of dynamin related protein 1 to promote cell death
US20150164896A1 (en) * 2013-12-13 2015-06-18 The Board Of Trustees Of The Leland Stanford Junior University Targeting a non-canonical notch signaling pathway for cancer treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004002470A1 (en) 2002-06-27 2004-01-08 The Endowment For Research In Human Biology, Inc. Compounds useful for the inhibition of aldh
AU2006303037A1 (en) 2005-10-21 2007-04-26 Merz Pharma Gmbh & Co Kgaa Chromenones and their use as modulators of metabotropic glutamate receptors
US9492450B2 (en) * 2011-04-19 2016-11-15 University of Pittsburgh—of the Commonwealth System of Higher Education Inhibition of dynamin related protein 1 to promote cell death
JP2013142070A (ja) 2012-01-11 2013-07-22 Nihon Univ ミトコンドリア分裂阻害剤を用いたｔｒａｉｌ抵抗性の克服
WO2014105751A1 (en) 2012-12-28 2014-07-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for treatment of mitochondrial diseases and for differentiation of cells to neurons
US9289448B2 (en) 2013-03-15 2016-03-22 Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for treating alzheimer's disease and other tauopathies
GB201522232D0 (en) 2015-12-16 2016-01-27 Liverpool School Tropical Medicine Combination product
US11186550B2 (en) 2017-09-13 2021-11-30 Cerepeut, Inc. Small molecule compound

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051974A2 (en) * 2003-06-09 2005-06-09 The Regents Of The University Of California Novel molecules for regulating cell death
US8450333B2 (en) * 2003-06-09 2013-05-28 The Regents Of The University Of California Molecules for regulating cell death
US8759097B2 (en) * 2011-04-19 2014-06-24 University of Pittsburgh—of the Commonwealth System of Higher Eduction Inhibition of dynamin related protein 1 to promote cell death
US20150164896A1 (en) * 2013-12-13 2015-06-18 The Board Of Trustees Of The Leland Stanford Junior University Targeting a non-canonical notch signaling pathway for cancer treatment

Also Published As

Publication number Publication date
AU2018331371A1 (en) 2020-04-02
US20200216400A1 (en) 2020-07-09
US11912669B2 (en) 2024-02-27
EP3681874A1 (en) 2020-07-22
US20220340534A1 (en) 2022-10-27
US20240246919A1 (en) 2024-07-25
CA3075649A1 (en) 2019-03-21
JP2020533399A (ja) 2020-11-19
EP3681874B1 (en) 2022-04-06
CN111372921A (zh) 2020-07-03
AU2018331371B2 (en) 2024-02-15
IL273242B2 (en) 2023-08-01
EP3681874A4 (en) 2021-01-13
KR102644045B1 (ko) 2024-03-05
KR20200053560A (ko) 2020-05-18
WO2019055528A1 (en) 2019-03-21
IL273242A (en) 2020-04-30
JP7170341B2 (ja) 2022-11-14
CN111372921B (zh) 2023-12-01
US12404251B2 (en) 2025-09-02
IL273242B1 (en) 2023-04-01
US11186550B2 (en) 2021-11-30

Similar Documents

Publication Publication Date Title
US12404251B2 (en) Small molecule compound
US20240374562A1 (en) Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
EP3510034B1 (en) Substituted imidazo-quinolines as nlrp3 modulators
KR102708250B1 (ko) 세스트린-gator2 상호작용의 조절제 및 이의 용도
KR20220102662A (ko) Nmdar 조절 화합물의 조합물
US20210085649A1 (en) Methods and use of compounds that bind to rela of nf-kb
US20240355686A1 (en) Clinical Methods and Pharmaceutical Compositions Employing AMPA Receptor Antagonists to Treat Glioblastoma and Other Cancers
CN109310650A (zh) 用于减少过表达c-myc的癌症中的c-myc的化合物
Song et al. Increased expression of Rho-associated protein kinase 2 confers astroglial Stat3 pathway activation during epileptogenesis
US12454514B2 (en) Quinazolinone compounds
KR102629173B1 (ko) 할로겐 함유 2,4-디페닐 인데노피리딘-5-온 유도체 및 이의 제조방법
WO2023053134A1 (en) Cannabinoids c- and o-glycosides possessing anti-proliferative and anti-metastatic properties and process for preparation thereof
CN100415219C (zh) 取代的二环[3.3.1]壬烷-2,4,9三酮作为活性药物成分
CN112999236B (zh) 乌本苷用于治疗脑干胶质瘤的用途
WO2017069913A1 (en) Chalcone compounds
KR20090091119A (ko) 뇌암을 치료하거나 예방하기 위한 ｍｔ 키나아제 저해제의 용도

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 09 FEB 2024

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 09 FEB 2024

FGA Letters patent sealed or granted (standard patent)